Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Corporate Controller and PFO | March 14, 2024 | March 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date March 14, 2024 · Filed March 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2024-03-14 transaction · row 1
1 source rowRow 1 · 2024-03-14 · Grant · Acquired 10,000 · Balance 10,000 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.38 · Expires 2034-03-14 | Direct | 40,000 |
Reported balance
After 2024-03-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-14 · Grant · Acquired 40,000 · Balance 40,000 F1: Twenty-five percent (25%) of the Stock Options shall vest on March 14th of each of 2025, 2026, 2027, and 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the Stock Options shall vest on March 14th of each of 2025, 2026, 2027, and 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2024 Filed Mar 19, 2024 00:02 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001104659-24-035728 · tm249071-7_4seq1.xml · derivative · entry 2 Rychlik Richard · CIK 0001994635 · Corporate Controller and PFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-03-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Stock Options shall vest on March 14th of each of 2025, 2026, 2027, and 2028. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:02 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-035728 · tm249071-7_4seq1.xml · nonDerivative · entry 1 Rychlik Richard · CIK 0001994635 · Corporate Controller and PFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| December 21, 2023 Filed Dec 27, 2023 02:54 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001104659-23-129367 · tm2333426-8_4seq1.xml · derivative · entry 1 Rychlik Richard · CIK 0001994635 · Corporate Controller and PFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_date: The Option shall vest in equal annual installments on each of the first four anniversaries of September 5, 2023. F1 · derivative.expiration_date: The Option shall vest in equal annual installments on each of the first four anniversaries of September 5, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.